Article
High-flying Pfizer may disappoint on Comirnaty and Paxlovid sales in Q1, analyst warns
Rating:
0.0
Views:
28
Likes:
1
Library:
1
Pfizer's BioNTech-partnered COVID-19 vaccine Comirnaty and its antiviral pill Paxlovid are destined to reap many billions in 2022, but the company's first-quarter pandemic haul may come in lighter | Pfizer's BioNTech-partnered COVID-19 vaccine Comirnaty and its antiviral pill Paxlovid are destined to reap many billions in 2022, but the company's first-quarter pandemic haul may come in lighter than previously thought, one group of analysts predicts.
Rate This Post
-
Education
-
Communication
-
Entertainment
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value